Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NRAS wild-type |
| Therapy | Cetuximab + Fluorouracil + Irinotecan + Leucovorin |
| Indication/Tumor Type | colorectal cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NRAS wild-type | colorectal cancer | predicted - sensitive | Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Phase III | Actionable | In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843). | 25605843 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25605843) | Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. | Full reference... |